Clinical Trial Update: Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis

View source ↗

Summary

Prospective study validating a pharmacological biomarker for low-dose rituximab in rheumatoid arthritis; the trial status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University Hospital, Tours | Conditions: Rheumatoid Arthritis (RA) | Status: NOT_YET_RECRUITING